Loading…

Pathological findings of progressive renal involvement in a patient with TAFRO syndrome

TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly) is thought of as an atypical type of idiopathic multicentric Castleman’s disease. Interleukin-6, vascular endothelial growth factor (VEGF), and other cytokines are considered etiological factors. A 45-year-old w...

Full description

Saved in:
Bibliographic Details
Published in:CEN case reports 2019-11, Vol.8 (4), p.239-245
Main Authors: Saito, Hirotaka, Tanaka, Kenichi, Fujiwara, Momoko, Iwasaki, Tsuyoshi, Numata, Tokutaro, Oda, Akira, Kanno, Makoto, Tanaka, Mizuko, Eiro, Masaaki, Satoh, Mamoru, Kazama, Junichiro James
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c525t-f155803564382f250e995156df1772c062c6be1ecdf5afd93c4322051a790e053
cites cdi_FETCH-LOGICAL-c525t-f155803564382f250e995156df1772c062c6be1ecdf5afd93c4322051a790e053
container_end_page 245
container_issue 4
container_start_page 239
container_title CEN case reports
container_volume 8
creator Saito, Hirotaka
Tanaka, Kenichi
Fujiwara, Momoko
Iwasaki, Tsuyoshi
Numata, Tokutaro
Oda, Akira
Kanno, Makoto
Tanaka, Mizuko
Eiro, Masaaki
Satoh, Mamoru
Kazama, Junichiro James
description TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly) is thought of as an atypical type of idiopathic multicentric Castleman’s disease. Interleukin-6, vascular endothelial growth factor (VEGF), and other cytokines are considered etiological factors. A 45-year-old woman was admitted to hospital with unknown fever and abdominal pain. She had thrombocytopenia, anasarca, proteinuria/hematuria, and slight hepatosplenomegaly. Based on her clinical course and laboratory data, she was diagnosed as having TAFRO syndrome. Kidney biopsy showed a membranoproliferative glomerulonephritis (MPGN)-like lesion containing lobulations of glomeruli, endothelial cell swelling, double contours of the glomerular basement membrane, and mesangiolysis. She was treated with methylprednisolone pulse (500 mg/day) and oral prednisolone (60 mg/day) therapy. The pleural effusion and ascites disappeared, and renal function normalized. Cyclosporine was added to prevent relapse. She went home, with no relapse 8 months after hospitalization. MPGN-like lesions were found frequently in patients with TAFRO syndrome in recent reports. However, there are few reports of pathologically confirmed cases of progressive renal involvement in TAFRO syndrome. The relationship between VEGF expression in renal tissue and the pathogenesis of renal injury in TAFRO syndrome was investigated in the present case.
doi_str_mv 10.1007/s13730-019-00400-9
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6820645</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2231908939</sourcerecordid><originalsourceid>FETCH-LOGICAL-c525t-f155803564382f250e995156df1772c062c6be1ecdf5afd93c4322051a790e053</originalsourceid><addsrcrecordid>eNp9kU9LxDAQxYMo7qJ-AQ_So5fqJGnazUWQxX8gKKJ4DDGddCNtsibdFb-9XXcVvXiaGd6blyE_Qg4pnFCA6jRRXnHIgcocoADI5RYZMypZXhSF3P7Vj8hBSq8AQHkBAuQuGXEKVQWiHJPne93PQhsaZ3SbWedr55uUBZvNY2gipuSWmEX0g-r8MrRL7ND3Q5_pbK57txreXT_LHs8vH-6y9OHrGDrcJztWtwkPNnWPPF1ePE6v89u7q5vp-W1uBBN9bqkQE-CiLPiEWSYApRRUlLWlVcUMlMyUL0jR1FZoW0tuCs4YCKorCQiC75Gzde588dJhbYZzom7VPLpOxw8VtFN_Fe9mqglLVU4YlMUq4HgTEMPbAlOvOpcMtq32GBZJMcaphInkcrCytdXEkFJE-_MMBbWCotZQ1ABFfUFRq6Wj3wf-rHwjGAx8bUiD5BuM6jUs4vDf6b_YTw8umBY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2231908939</pqid></control><display><type>article</type><title>Pathological findings of progressive renal involvement in a patient with TAFRO syndrome</title><source>NCBI_PubMed Central(免费)</source><source>Springer Nature</source><creator>Saito, Hirotaka ; Tanaka, Kenichi ; Fujiwara, Momoko ; Iwasaki, Tsuyoshi ; Numata, Tokutaro ; Oda, Akira ; Kanno, Makoto ; Tanaka, Mizuko ; Eiro, Masaaki ; Satoh, Mamoru ; Kazama, Junichiro James</creator><creatorcontrib>Saito, Hirotaka ; Tanaka, Kenichi ; Fujiwara, Momoko ; Iwasaki, Tsuyoshi ; Numata, Tokutaro ; Oda, Akira ; Kanno, Makoto ; Tanaka, Mizuko ; Eiro, Masaaki ; Satoh, Mamoru ; Kazama, Junichiro James</creatorcontrib><description>TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly) is thought of as an atypical type of idiopathic multicentric Castleman’s disease. Interleukin-6, vascular endothelial growth factor (VEGF), and other cytokines are considered etiological factors. A 45-year-old woman was admitted to hospital with unknown fever and abdominal pain. She had thrombocytopenia, anasarca, proteinuria/hematuria, and slight hepatosplenomegaly. Based on her clinical course and laboratory data, she was diagnosed as having TAFRO syndrome. Kidney biopsy showed a membranoproliferative glomerulonephritis (MPGN)-like lesion containing lobulations of glomeruli, endothelial cell swelling, double contours of the glomerular basement membrane, and mesangiolysis. She was treated with methylprednisolone pulse (500 mg/day) and oral prednisolone (60 mg/day) therapy. The pleural effusion and ascites disappeared, and renal function normalized. Cyclosporine was added to prevent relapse. She went home, with no relapse 8 months after hospitalization. MPGN-like lesions were found frequently in patients with TAFRO syndrome in recent reports. However, there are few reports of pathologically confirmed cases of progressive renal involvement in TAFRO syndrome. The relationship between VEGF expression in renal tissue and the pathogenesis of renal injury in TAFRO syndrome was investigated in the present case.</description><identifier>ISSN: 2192-4449</identifier><identifier>EISSN: 2192-4449</identifier><identifier>DOI: 10.1007/s13730-019-00400-9</identifier><identifier>PMID: 31077056</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Abdominal Pain - diagnosis ; Abdominal Pain - etiology ; Anti-Inflammatory Agents - administration &amp; dosage ; Anti-Inflammatory Agents - therapeutic use ; Case Report ; Castleman Disease - blood ; Castleman Disease - diagnosis ; Castleman Disease - drug therapy ; Castleman Disease - pathology ; Cyclosporine - administration &amp; dosage ; Cyclosporine - therapeutic use ; Female ; Fever - diagnosis ; Fever - etiology ; Glomerulonephritis, Membranoproliferative - pathology ; Humans ; Immunosuppressive Agents - administration &amp; dosage ; Immunosuppressive Agents - therapeutic use ; Kidney - blood supply ; Kidney - pathology ; Kidney Glomerulus - pathology ; Medicine ; Medicine &amp; Public Health ; Methylprednisolone - administration &amp; dosage ; Methylprednisolone - therapeutic use ; Middle Aged ; Nephrology ; Thrombocytopenia - diagnosis ; Thrombocytopenia - etiology ; Treatment Outcome ; Urology ; Vascular Endothelial Growth Factor A - metabolism</subject><ispartof>CEN case reports, 2019-11, Vol.8 (4), p.239-245</ispartof><rights>Japanese Society of Nephrology 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c525t-f155803564382f250e995156df1772c062c6be1ecdf5afd93c4322051a790e053</citedby><cites>FETCH-LOGICAL-c525t-f155803564382f250e995156df1772c062c6be1ecdf5afd93c4322051a790e053</cites><orcidid>0000-0003-4655-9355</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820645/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820645/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31077056$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saito, Hirotaka</creatorcontrib><creatorcontrib>Tanaka, Kenichi</creatorcontrib><creatorcontrib>Fujiwara, Momoko</creatorcontrib><creatorcontrib>Iwasaki, Tsuyoshi</creatorcontrib><creatorcontrib>Numata, Tokutaro</creatorcontrib><creatorcontrib>Oda, Akira</creatorcontrib><creatorcontrib>Kanno, Makoto</creatorcontrib><creatorcontrib>Tanaka, Mizuko</creatorcontrib><creatorcontrib>Eiro, Masaaki</creatorcontrib><creatorcontrib>Satoh, Mamoru</creatorcontrib><creatorcontrib>Kazama, Junichiro James</creatorcontrib><title>Pathological findings of progressive renal involvement in a patient with TAFRO syndrome</title><title>CEN case reports</title><addtitle>CEN Case Rep</addtitle><addtitle>CEN Case Rep</addtitle><description>TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly) is thought of as an atypical type of idiopathic multicentric Castleman’s disease. Interleukin-6, vascular endothelial growth factor (VEGF), and other cytokines are considered etiological factors. A 45-year-old woman was admitted to hospital with unknown fever and abdominal pain. She had thrombocytopenia, anasarca, proteinuria/hematuria, and slight hepatosplenomegaly. Based on her clinical course and laboratory data, she was diagnosed as having TAFRO syndrome. Kidney biopsy showed a membranoproliferative glomerulonephritis (MPGN)-like lesion containing lobulations of glomeruli, endothelial cell swelling, double contours of the glomerular basement membrane, and mesangiolysis. She was treated with methylprednisolone pulse (500 mg/day) and oral prednisolone (60 mg/day) therapy. The pleural effusion and ascites disappeared, and renal function normalized. Cyclosporine was added to prevent relapse. She went home, with no relapse 8 months after hospitalization. MPGN-like lesions were found frequently in patients with TAFRO syndrome in recent reports. However, there are few reports of pathologically confirmed cases of progressive renal involvement in TAFRO syndrome. The relationship between VEGF expression in renal tissue and the pathogenesis of renal injury in TAFRO syndrome was investigated in the present case.</description><subject>Abdominal Pain - diagnosis</subject><subject>Abdominal Pain - etiology</subject><subject>Anti-Inflammatory Agents - administration &amp; dosage</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Case Report</subject><subject>Castleman Disease - blood</subject><subject>Castleman Disease - diagnosis</subject><subject>Castleman Disease - drug therapy</subject><subject>Castleman Disease - pathology</subject><subject>Cyclosporine - administration &amp; dosage</subject><subject>Cyclosporine - therapeutic use</subject><subject>Female</subject><subject>Fever - diagnosis</subject><subject>Fever - etiology</subject><subject>Glomerulonephritis, Membranoproliferative - pathology</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration &amp; dosage</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Kidney - blood supply</subject><subject>Kidney - pathology</subject><subject>Kidney Glomerulus - pathology</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Methylprednisolone - administration &amp; dosage</subject><subject>Methylprednisolone - therapeutic use</subject><subject>Middle Aged</subject><subject>Nephrology</subject><subject>Thrombocytopenia - diagnosis</subject><subject>Thrombocytopenia - etiology</subject><subject>Treatment Outcome</subject><subject>Urology</subject><subject>Vascular Endothelial Growth Factor A - metabolism</subject><issn>2192-4449</issn><issn>2192-4449</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kU9LxDAQxYMo7qJ-AQ_So5fqJGnazUWQxX8gKKJ4DDGddCNtsibdFb-9XXcVvXiaGd6blyE_Qg4pnFCA6jRRXnHIgcocoADI5RYZMypZXhSF3P7Vj8hBSq8AQHkBAuQuGXEKVQWiHJPne93PQhsaZ3SbWedr55uUBZvNY2gipuSWmEX0g-r8MrRL7ND3Q5_pbK57txreXT_LHs8vH-6y9OHrGDrcJztWtwkPNnWPPF1ePE6v89u7q5vp-W1uBBN9bqkQE-CiLPiEWSYApRRUlLWlVcUMlMyUL0jR1FZoW0tuCs4YCKorCQiC75Gzde588dJhbYZzom7VPLpOxw8VtFN_Fe9mqglLVU4YlMUq4HgTEMPbAlOvOpcMtq32GBZJMcaphInkcrCytdXEkFJE-_MMBbWCotZQ1ABFfUFRq6Wj3wf-rHwjGAx8bUiD5BuM6jUs4vDf6b_YTw8umBY</recordid><startdate>20191101</startdate><enddate>20191101</enddate><creator>Saito, Hirotaka</creator><creator>Tanaka, Kenichi</creator><creator>Fujiwara, Momoko</creator><creator>Iwasaki, Tsuyoshi</creator><creator>Numata, Tokutaro</creator><creator>Oda, Akira</creator><creator>Kanno, Makoto</creator><creator>Tanaka, Mizuko</creator><creator>Eiro, Masaaki</creator><creator>Satoh, Mamoru</creator><creator>Kazama, Junichiro James</creator><general>Springer Singapore</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4655-9355</orcidid></search><sort><creationdate>20191101</creationdate><title>Pathological findings of progressive renal involvement in a patient with TAFRO syndrome</title><author>Saito, Hirotaka ; Tanaka, Kenichi ; Fujiwara, Momoko ; Iwasaki, Tsuyoshi ; Numata, Tokutaro ; Oda, Akira ; Kanno, Makoto ; Tanaka, Mizuko ; Eiro, Masaaki ; Satoh, Mamoru ; Kazama, Junichiro James</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c525t-f155803564382f250e995156df1772c062c6be1ecdf5afd93c4322051a790e053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Abdominal Pain - diagnosis</topic><topic>Abdominal Pain - etiology</topic><topic>Anti-Inflammatory Agents - administration &amp; dosage</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Case Report</topic><topic>Castleman Disease - blood</topic><topic>Castleman Disease - diagnosis</topic><topic>Castleman Disease - drug therapy</topic><topic>Castleman Disease - pathology</topic><topic>Cyclosporine - administration &amp; dosage</topic><topic>Cyclosporine - therapeutic use</topic><topic>Female</topic><topic>Fever - diagnosis</topic><topic>Fever - etiology</topic><topic>Glomerulonephritis, Membranoproliferative - pathology</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration &amp; dosage</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Kidney - blood supply</topic><topic>Kidney - pathology</topic><topic>Kidney Glomerulus - pathology</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Methylprednisolone - administration &amp; dosage</topic><topic>Methylprednisolone - therapeutic use</topic><topic>Middle Aged</topic><topic>Nephrology</topic><topic>Thrombocytopenia - diagnosis</topic><topic>Thrombocytopenia - etiology</topic><topic>Treatment Outcome</topic><topic>Urology</topic><topic>Vascular Endothelial Growth Factor A - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saito, Hirotaka</creatorcontrib><creatorcontrib>Tanaka, Kenichi</creatorcontrib><creatorcontrib>Fujiwara, Momoko</creatorcontrib><creatorcontrib>Iwasaki, Tsuyoshi</creatorcontrib><creatorcontrib>Numata, Tokutaro</creatorcontrib><creatorcontrib>Oda, Akira</creatorcontrib><creatorcontrib>Kanno, Makoto</creatorcontrib><creatorcontrib>Tanaka, Mizuko</creatorcontrib><creatorcontrib>Eiro, Masaaki</creatorcontrib><creatorcontrib>Satoh, Mamoru</creatorcontrib><creatorcontrib>Kazama, Junichiro James</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>CEN case reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saito, Hirotaka</au><au>Tanaka, Kenichi</au><au>Fujiwara, Momoko</au><au>Iwasaki, Tsuyoshi</au><au>Numata, Tokutaro</au><au>Oda, Akira</au><au>Kanno, Makoto</au><au>Tanaka, Mizuko</au><au>Eiro, Masaaki</au><au>Satoh, Mamoru</au><au>Kazama, Junichiro James</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pathological findings of progressive renal involvement in a patient with TAFRO syndrome</atitle><jtitle>CEN case reports</jtitle><stitle>CEN Case Rep</stitle><addtitle>CEN Case Rep</addtitle><date>2019-11-01</date><risdate>2019</risdate><volume>8</volume><issue>4</issue><spage>239</spage><epage>245</epage><pages>239-245</pages><issn>2192-4449</issn><eissn>2192-4449</eissn><abstract>TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly) is thought of as an atypical type of idiopathic multicentric Castleman’s disease. Interleukin-6, vascular endothelial growth factor (VEGF), and other cytokines are considered etiological factors. A 45-year-old woman was admitted to hospital with unknown fever and abdominal pain. She had thrombocytopenia, anasarca, proteinuria/hematuria, and slight hepatosplenomegaly. Based on her clinical course and laboratory data, she was diagnosed as having TAFRO syndrome. Kidney biopsy showed a membranoproliferative glomerulonephritis (MPGN)-like lesion containing lobulations of glomeruli, endothelial cell swelling, double contours of the glomerular basement membrane, and mesangiolysis. She was treated with methylprednisolone pulse (500 mg/day) and oral prednisolone (60 mg/day) therapy. The pleural effusion and ascites disappeared, and renal function normalized. Cyclosporine was added to prevent relapse. She went home, with no relapse 8 months after hospitalization. MPGN-like lesions were found frequently in patients with TAFRO syndrome in recent reports. However, there are few reports of pathologically confirmed cases of progressive renal involvement in TAFRO syndrome. The relationship between VEGF expression in renal tissue and the pathogenesis of renal injury in TAFRO syndrome was investigated in the present case.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>31077056</pmid><doi>10.1007/s13730-019-00400-9</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-4655-9355</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2192-4449
ispartof CEN case reports, 2019-11, Vol.8 (4), p.239-245
issn 2192-4449
2192-4449
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6820645
source NCBI_PubMed Central(免费); Springer Nature
subjects Abdominal Pain - diagnosis
Abdominal Pain - etiology
Anti-Inflammatory Agents - administration & dosage
Anti-Inflammatory Agents - therapeutic use
Case Report
Castleman Disease - blood
Castleman Disease - diagnosis
Castleman Disease - drug therapy
Castleman Disease - pathology
Cyclosporine - administration & dosage
Cyclosporine - therapeutic use
Female
Fever - diagnosis
Fever - etiology
Glomerulonephritis, Membranoproliferative - pathology
Humans
Immunosuppressive Agents - administration & dosage
Immunosuppressive Agents - therapeutic use
Kidney - blood supply
Kidney - pathology
Kidney Glomerulus - pathology
Medicine
Medicine & Public Health
Methylprednisolone - administration & dosage
Methylprednisolone - therapeutic use
Middle Aged
Nephrology
Thrombocytopenia - diagnosis
Thrombocytopenia - etiology
Treatment Outcome
Urology
Vascular Endothelial Growth Factor A - metabolism
title Pathological findings of progressive renal involvement in a patient with TAFRO syndrome
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T05%3A00%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pathological%20findings%20of%20progressive%20renal%20involvement%20in%20a%20patient%20with%20TAFRO%20syndrome&rft.jtitle=CEN%20case%20reports&rft.au=Saito,%20Hirotaka&rft.date=2019-11-01&rft.volume=8&rft.issue=4&rft.spage=239&rft.epage=245&rft.pages=239-245&rft.issn=2192-4449&rft.eissn=2192-4449&rft_id=info:doi/10.1007/s13730-019-00400-9&rft_dat=%3Cproquest_pubme%3E2231908939%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c525t-f155803564382f250e995156df1772c062c6be1ecdf5afd93c4322051a790e053%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2231908939&rft_id=info:pmid/31077056&rfr_iscdi=true